CANCER BIOPSY MARKET ANALYSIS
Global Cancer Biopsy Market: Key Developments
In August 2022, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic (CDx) to choose patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) with tumors that have activating HER2 mutations for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
In July 2022, BillionToOne Inc. announced the launch of its first oncology liquid biopsy product, Northstar Select and Northstar Response. These products are currently available for research use with selected academic cancer centres.
In May 2022, Delfi Diagnostics, a developer of a new class of high-performance, affordable liquid biopsy tests for the early cancer detection, presented multiple applications for its next-generation liquid biopsy platform. Delfi presented a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 